{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T13:09:55Z","timestamp":1769692195483,"version":"3.49.0"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T00:00:00Z","timestamp":1637020800000},"content-version":"vor","delay-in-days":573,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2019-01034"],"award-info":[{"award-number":["2019-01034"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ragna and Paul Nyberg Foundation"},{"DOI":"10.13039\/501100003793","name":"Hj\u00e4rt-Lungfonden","doi-asserted-by":"crossref","award":["20190478"],"award-info":[{"award-number":["20190478"]}],"id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006129","name":"Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004348","name":"Stockholms L\u00e4ns Landsting","doi-asserted-by":"publisher","award":["20180120"],"award-info":[{"award-number":["20180120"]}],"id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,11]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>Pulmonary sarcoidosis is characterized by an exaggerated CD4+ T cell response and formation of non-necrotizing granulomas. Tumour necrosis factor \u03b1 (TNF-\u03b1) is regarded as crucial for granuloma formation and TNF-\u03b1 inhibitors offer a third-line treatment option for patients not responding to conventional treatment. However, not all patients benefit from treatment, and an optimal dose and treatment duration have not been established. Insight into the influence of TNF-\u03b1 inhibitors on lung immune cells may provide clues as to what drives inflammation in sarcoidosis and improve our understanding of treatment outcomes. To evaluate the effects of treatment with the TNF-\u03b1 inhibitor infliximab on lung immune cells and clinical features of the patients, 13\u00a0patients with sarcoidosis refractory to conventional treatment were assessed with bronchoalveolar lavage (BAL), spirometry and computerized tomography (CT) scan closely adjacent to the start of infliximab treatment. These investigations were repeated after 6\u00a0months of treatment. Treatment with TNF-\u03b1 inhibitor infliximab was well tolerated with no adverse events, except for one patient who developed a probable adverse event with liver toxicity. Ten patients were classified as responders, having a reduced CD4\/CD8 ratio, a decreased percentage of CD4+ T cells expressing the activation marker CD69 and number of mast cells (P\u00a0&amp;lt;\u00a00\u00b705 for all). The percentage of T regulatory cells (Tregs), defined as forkhead box P3+ CD4+ T cells decreased in most patients. In conclusion, six months of infliximab treatment in patients with sarcoidosis led to signs of decreased CD4+ T cell alveolitis and decreased mastocytosis in the lungs of responders.<\/jats:p>","DOI":"10.1111\/cei.13438","type":"journal-article","created":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T18:29:16Z","timestamp":1586543356000},"page":"85-93","source":"Crossref","is-referenced-by-count":12,"title":["Changes in lung immune cells related to clinical outcome during treatment with infliximab for sarcoidosis"],"prefix":"10.1093","volume":"201","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2844-4773","authenticated-orcid":false,"given":"S","family":"Kullberg","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Theme Inflammation and Infection, Karolinska University Hospital, Stockholm, Sweden"},{"name":"Respiratory Medicine Division, Department of Medicine, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N V","family":"Rivera","sequence":"additional","affiliation":[{"name":"Respiratory Medicine Division, Department of Medicine, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Abo Al Hayja","sequence":"additional","affiliation":[{"name":"Respiratory Medicine Division, Department of Medicine, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Grunewald","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Theme Inflammation and Infection, Karolinska University Hospital, Stockholm, Sweden"},{"name":"Respiratory Medicine Division, Department of Medicine, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Eklund","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Theme Inflammation and Infection, Karolinska University Hospital, Stockholm, Sweden"},{"name":"Respiratory Medicine Division, Department of Medicine, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,4,22]]},"reference":[{"key":"2022011418210596700_cei13438-bib-0001","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-019-0096-x","article-title":"Sarcoidosis","volume":"5","author":"Grunewald","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"2022011418210596700_cei13438-bib-0002","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1164\/ajrccm\/145.1.187","article-title":"Lung-restricted activation of the alveolar macrophage\/monocyte system in pulmonary sarcoidosis","volume":"145","author":"Muller-Quernheim","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"2022011418210596700_cei13438-bib-0003","first-page":"185","article-title":"Exaggerated TNFalpha release of alveolar macrophages in corticosteroid resistant sarcoidosis","volume":"19","author":"Ziegenhagen","year":"2002","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2022011418210596700_cei13438-bib-0004","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.autrev.2014.10.012","article-title":"Regulatory T-cells in autoimmune diseases: challenges, controversies and-yet-unanswered questions","volume":"14","author":"Grant","year":"2015","journal-title":"Autoimmun Rev"},{"key":"2022011418210596700_cei13438-bib-0005","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1365-2249.2008.03609.x","article-title":"Analysis of regulatory T cell associated forkhead box P3 expression in the lungs of patients with sarcoidosis","volume":"152","author":"Idali","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"2022011418210596700_cei13438-bib-0006","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1084\/jem.20050648","article-title":"The immune paradox of sarcoidosis and regulatory T cells","volume":"203","author":"Miyara","year":"2006","journal-title":"J Exp Med"},{"key":"2022011418210596700_cei13438-bib-0007","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1183\/09031936.97.10122699","article-title":"CD4\/CD8 ratios in bronchoalveolar lavage fluid: of value for diagnosing sarcoidosis?","volume":"10","author":"Costabel","year":"1997","journal-title":"Eur Respir J"},{"key":"2022011418210596700_cei13438-bib-0008","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1164\/ajrccm.163.1.9906071","article-title":"Analysis of intracellular cytokines in CD4+ and CD8+ lung and blood T cells in sarcoidosis","volume":"163","author":"Wahlstrom","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"2022011418210596700_cei13438-bib-0009","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.rmed.2017.10.006","article-title":"Enhanced CD8(+) cytolytic T cell responses in the peripheral circulation of patients with sarcoidosis and non-Lofgren's disease","volume":"138s","author":"Parasa","year":"2018","journal-title":"Respir Med"},{"key":"2022011418210596700_cei13438-bib-0010","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1183\/09031936.96.09010047","article-title":"Pulmonary sarcoidosis: patterns of cytokine release in vitro","volume":"9","author":"Prior","year":"1996","journal-title":"Eur Respir J"},{"key":"2022011418210596700_cei13438-bib-0011","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1183\/09031936.03.00083002","article-title":"Alveolar macrophages are the main source for tumour necrosis factor-alpha in patients with sarcoidosis","volume":"21","author":"Fehrenbach","year":"2003","journal-title":"Eur Respir J"},{"key":"2022011418210596700_cei13438-bib-0012","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/346274a0","article-title":"Mast cells as a source of both preformed and immunologically inducible TNF-alpha\/cachectin","volume":"346","author":"Gordon","year":"1990","journal-title":"Nature"},{"key":"2022011418210596700_cei13438-bib-0013","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1182\/blood-2006-09-046128","article-title":"Mast cell-derived TNF can promote Th17 cell-dependent neutrophil recruitment in ovalbumin-challenged OTII mice","volume":"109","author":"Nakae","year":"2007","journal-title":"Blood"},{"key":"2022011418210596700_cei13438-bib-0014","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1046\/j.1365-2249.2000.01365.x","article-title":"Th1 cytokine pattern in sarcoidosis is expressed by bronchoalveolar CD4+ and CD8+ T cells","volume":"122","author":"Prasse","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"2022011418210596700_cei13438-bib-0015","first-page":"12","article-title":"Elevated levels of tryptase in bronchoalveolar lavage fluid from patients with sarcoidosis","volume":"10","author":"Eklund","year":"1993","journal-title":"Sarcoidosis"},{"key":"2022011418210596700_cei13438-bib-0016","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1136\/thx.41.2.94","article-title":"Bronchoalveolar mast cells in sarcoidosis: increased numbers and accentuation of mediator release","volume":"41","author":"Flint","year":"1986","journal-title":"Thorax"},{"key":"2022011418210596700_cei13438-bib-0017","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1136\/thx.42.12.933","article-title":"Hyaluronic acid in bronchoalveolar lavage fluid in patients with sarcoidosis: relationship to lavage mast cells","volume":"42","author":"Bjermer","year":"1987","journal-title":"Thorax"},{"key":"2022011418210596700_cei13438-bib-0018","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000195476","article-title":"Mast cells in bronchoalveolar lavage in sarcoidosis: correlation with alveolar lymphocytes","volume":"54","author":"Rottoli","year":"1988","journal-title":"Respiration"},{"key":"2022011418210596700_cei13438-bib-0019","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/thx.43.4.284","article-title":"Predictive value of bronchoalveolar lavage cell analysis in sarcoidosis","volume":"43","author":"Bjermer","year":"1988","journal-title":"Thorax"},{"key":"2022011418210596700_cei13438-bib-0020","first-page":"91","article-title":"Practical eminence and experience-based recommendations for use of TNF-\u03b1 inhibitors in sarcoidosis","volume":"31","author":"Drent","year":"2014","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2022011418210596700_cei13438-bib-0021","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.semarthrit.2018.10.005","article-title":"Anti-tumor necrosis factor agents in sarcoidosis: a systematic review of efficacy and safety","volume":"48","author":"Adler","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2022011418210596700_cei13438-bib-0022","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1183\/09031936.00055213","article-title":"Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis","volume":"43","author":"Vorselaars","year":"2014","journal-title":"Eur Respir J"},{"key":"2022011418210596700_cei13438-bib-0023","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1183\/09031936.00227014","article-title":"Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis","volume":"46","author":"Vorselaars","year":"2015","journal-title":"Eur Respir J"},{"key":"2022011418210596700_cei13438-bib-0024","first-page":"49","article-title":"C-reactive protein predicts response to infliximab in patients with chronic sarcoidosis","volume":"27","author":"Sweiss","year":"2010","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2022011418210596700_cei13438-bib-0025","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1128\/CVI.00337-10","article-title":"Inflammatory profile and response to anti-tumor necrosis factor therapy in patients with chronic pulmonary sarcoidosis","volume":"18","author":"Loza","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"2022011418210596700_cei13438-bib-0026","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/cei.12808","article-title":"Infliximab therapy balances regulatory T cells, tumour necrosis factor receptor 2 (TNFR2) expression and soluble TNFR2 in sarcoidosis","volume":"185","author":"Verwoerd","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"2022011418210596700_cei13438-bib-0027","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1183\/13993003.00709-2016","article-title":"Can intermediate monocytes predict response to infliximab therapy in sarcoidosis?","volume":"48","author":"Hijdra","year":"2016","journal-title":"Eur Respir J"},{"key":"2022011418210596700_cei13438-bib-0028","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1183\/13993003.00092-2016","article-title":"Expanded lung T-bet+RORgammaT+ CD4+ T-cells in sarcoidosis patients with a favourable disease phenotype","volume":"48","author":"Kaiser","year":"2016","journal-title":"Eur Respir J"},{"key":"2022011418210596700_cei13438-bib-0029","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1365-2796.2012.02543.x","article-title":"T-cell phenotypes in bronchoalveolar lavage fluid, blood and lymph nodes in pulmonary sarcoidosis\u2013indication for an airborne antigen as the triggering factor in sarcoidosis","volume":"272","author":"Darlington","year":"2012","journal-title":"J Intern Med"},{"key":"2022011418210596700_cei13438-bib-0030","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/cei.12715","article-title":"Pulmonary sarcoidosis is associated with high-level inducible co-stimulator (ICOS) expression on lung regulatory T cells\u2013possible implications for the ICOS\/ICOS-ligand axis in disease course and resolution","volume":"183","author":"Sakthivel","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"2022011418210596700_cei13438-bib-0031","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1164\/ajrccm\/140.1.82","article-title":"Interleukin-2 receptor gene expression by bronchoalveolar lavage lymphocytes in pulmonary sarcoidosis","volume":"140","author":"Muller-Quernheim","year":"1989","journal-title":"Am Rev Respir Dis"},{"key":"2022011418210596700_cei13438-bib-0032","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1164\/ajrccm.163.7.2005028","article-title":"Highly activated T-cell receptor AV2S3(+) CD4(+) lung T-cell expansions in pulmonary sarcoidosis","volume":"163","author":"Katchar","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"2022011418210596700_cei13438-bib-0033","first-page":"149","article-title":"ATS\/ERS\/WASOG statement on sarcoidosis. American Thoracic Society\/European Respiratory Society\/World Association of Sarcoidosis and other Granulomatous Disorders","volume":"16","author":"Hunninghake","year":"1999","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2022011418210596700_cei13438-bib-0034","doi-asserted-by":"crossref","first-page":"e43644","DOI":"10.1371\/journal.pone.0043644","article-title":"Bronchoalveolar lavage results are independent of season, age, gender and collection site","volume":"7","author":"Olsen","year":"2012","journal-title":"PLOS ONE"},{"key":"2022011418210596700_cei13438-bib-0035","first-page":"90","article-title":"Endpoints for clinical trials of sarcoidosis","volume":"29","author":"Baughman","year":"2012","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2022011418210596700_cei13438-bib-0036","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","article-title":"Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement","volume":"174","author":"Baughman","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2022011418210596700_cei13438-bib-0037","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1183\/09031936.00169413","article-title":"Association of the TNF-\u03b1 G-308A polymorphism with TNF-inhibitor response in sarcoidosis","volume":"43","author":"Wijnen","year":"2014","journal-title":"Eur Respir J"},{"key":"2022011418210596700_cei13438-bib-0038","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3389\/fimmu.2012.00006","article-title":"T cell-mediated modulation of mast cell function: heterotypic adhesion-induced stimulatory or inhibitory effects","volume":"3","author":"Mekori","year":"2012","journal-title":"Front Immunol"},{"key":"2022011418210596700_cei13438-bib-0039","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.1158\/0008-5472.CAN-09-0304","article-title":"T-regulatory cells shift from a protective anti-inflammatory to a cancer-promoting proinflammatory phenotype in polyposis","volume":"69","author":"Gounaris","year":"2009","journal-title":"Cancer Res"},{"key":"2022011418210596700_cei13438-bib-0040","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.immuni.2009.08.022","article-title":"Mast cell-mediated antigen presentation regulates CD8+ T cell effector functions","volume":"31","author":"Stelekati","year":"2009","journal-title":"Immunity"},{"key":"2022011418210596700_cei13438-bib-0041","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/ni1005","article-title":"Mast cell-derived tumor necrosis factor induces hypertrophy of draining lymph nodes during infection","volume":"4","author":"McLachlan","year":"2003","journal-title":"Nat Immunol"},{"key":"2022011418210596700_cei13438-bib-0042","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1183\/09031936.03.00059103","article-title":"Markers of activity in clinically recovered human leukocyte antigen-DR17-positive sarcoidosis patients","volume":"21","author":"Planck","year":"2003","journal-title":"Eur Respir J"},{"key":"2022011418210596700_cei13438-bib-0043","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4049\/jimmunol.179.1.154","article-title":"Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells","volume":"179","author":"Chen","year":"2007","journal-title":"J Immunol"},{"key":"2022011418210596700_cei13438-bib-0044","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/nm.3085","article-title":"Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-\u03b1 in rheumatoid arthritis","volume":"19","author":"Nie","year":"2013","journal-title":"Nat Med"},{"key":"2022011418210596700_cei13438-bib-0045","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1084\/jem.20061531","article-title":"Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta","volume":"204","author":"Nadkarni","year":"2007","journal-title":"J Exp Med"},{"key":"2022011418210596700_cei13438-bib-0046","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1093\/rheumatology\/keq449","article-title":"Potential biomarkers of monocyte\/macrophage activity in a patient with sarcoidosis, treated with infliximab","volume":"50","author":"Fang","year":"2011","journal-title":"Rheumatology"},{"key":"2022011418210596700_cei13438-bib-0047","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1172\/JCI38482","article-title":"Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans","volume":"119","author":"Bruns","year":"2009","journal-title":"J Clin Invest"},{"key":"2022011418210596700_cei13438-bib-0048","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41590-018-0120-4","article-title":"Regulatory T cells in autoimmune disease","volume":"19","author":"Dominguez-Villar","year":"2018","journal-title":"Nat Immunol"},{"key":"2022011418210596700_cei13438-bib-0049","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1164\/rccm.200909-1451OC","article-title":"Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis","volume":"182","author":"Prasse","year":"2010","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcei.13438","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cei.13438","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cei.13438","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/201\/1\/85\/42195711\/cei13438.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/201\/1\/85\/42195711\/cei13438.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T19:04:25Z","timestamp":1642187065000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/201\/1\/85\/6401631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,22]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,4,22]]},"published-print":{"date-parts":[[2020,6,11]]}},"URL":"https:\/\/doi.org\/10.1111\/cei.13438","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,7]]},"published":{"date-parts":[[2020,4,22]]}}}